Overview

Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

Status:
Completed

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

This Phase II study is designed to evaluate the antitumor efficacy and pharmacokinetics of crenolanib (CP-868,596) in patients with D842-related mutant metastatic GIST.

Phase:

Phase 2

Details

Lead Sponsor:

Arog Pharmaceuticals, Inc.

Treatments:

Crenolanib